ACT Advisors’s Compass Therapeutics CMPX Stock Holding History

ACT Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17.8K	Sell	17,143 -3,470	-17%	-$7.15K	0.01%	79
2026 Q2	$45.1K	Buy	+20,613	New	+$60.9K	0.02%	73
2025 Q4	–	Sell	-10,376	Closed	-$36.3K	–	68
2025 Q3	$36.3K	Hold	10,376	–	–	0.01%	66
2025 Q2	$27K	Sell	10,376 -385	-4%	-$794	0.01%	57
2025 Q1	$20.4K	Buy	10,761 +233	+2%	+$620	0.01%	54
2024 Q4	$15.3K	Buy	+10,528	New	+$17.5K	0.01%	53

Other funds holding CMPX

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

ACT Advisors's CMPX Position: Q3 2026 in Review

ACT Advisors reduced its Compass Therapeutics (CMPX) stake by 17% in Q3 2026, selling an estimated $7.15K and leaving 17,143 shares worth $17.8K. The position accounts for 0.01% of the portfolio, ranked #79.

ACT Advisors first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $45.1K in Q2 2026. 13 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

ACT Advisors held 17,143 shares of Compass Therapeutics worth $17.8K as of Q3 2026.
ACT Advisors sold 3,470 Compass Therapeutics shares in Q3 2026, an estimated $7.15K.
Compass Therapeutics made up 0.01% of ACT Advisors's portfolio in Q3 2026, its #79 holding.
ACT Advisors first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
ACT Advisors's Compass Therapeutics position peaked at $45.1K in Q2 2026.
13 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on ACT Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.